期刊
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
卷 42, 期 1, 页码 E48-E60出版社
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1161/ATV.0000000000000147
关键词
AHA Scientific Statements; apolipoprotein B100; atherosclerotic cardiovascular disease; cholesterol; low-density lipoprotein; lipoprotein(a)
High levels of Lp(a) are an independent and causal risk factor for atherosclerotic cardiovascular diseases. Genetic factors determine 70% to 90% of interindividual heterogeneity in Lp(a) levels. There is a lack of standardized assays, diagnostic guidelines, and targeted treatments for lowering Lp(a). Understanding the genetic and biological basis for variation in Lp(a) levels in different populations is crucial.
High levels of lipoprotein(a) [Lp(a)], an apoB100-containing lipoprotein, are an independent and causal risk factor for atherosclerotic cardiovascular diseases through mechanisms associated with increased atherogenesis, inflammation, and thrombosis. Lp(a) is predominantly a monogenic cardiovascular risk determinant, with approximate to 70% to >= 90% of interindividual heterogeneity in levels being genetically determined. The 2 major protein components of Lp(a) particles are apoB100 and apolipoprotein(a). Lp(a) remains a risk factor for cardiovascular disease development even in the setting of effective reduction of plasma low-density lipoprotein cholesterol and apoB100. Despite its demonstrated contribution to atherosclerotic cardiovascular disease burden, we presently lack standardization and harmonization of assays, universal guidelines for diagnosing and providing risk assessment, and targeted treatments to lower Lp(a). There is a clinical need to understand the genetic and biological basis for variation in Lp(a) levels and its relationship to disease in different ancestry groups. This scientific statement capitalizes on the expertise of a diverse basic science and clinical workgroup to highlight the history, biology, pathophysiology, and emerging clinical evidence in the Lp(a) field. Herein, we address key knowledge gaps and future directions required to mitigate the atherosclerotic cardiovascular disease risk attributable to elevated Lp(a) levels.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据